Clinical Trial Update: Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL [EARLY_Phase 1]

View source ↗

Summary

An early-phase Phase 1 study of a novel TLR2-containing CAR-T cell therapy targeting CD19 and CD22 for relapsed/refractory B-cell acute lymphoblastic leukemia a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• TLR2-containing CAR-T cells targeting CD19 and CD22

Snippet

Sponsor: Tongji Hospital | Conditions: R/R NHL | EARLY_Phase 1 | Status: NOT_YET_RECRUITING